Clinical trial
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous…
NCT00206089 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00206089 |
|---|---|
| Title | Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events |
| Official title | The "EXTEND" Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture… |
| Acronym | EXTEND |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | EXANTA |
| Enrollment | 3,300 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 15, 2010 |
| Countries | Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Mexico, Netherlands, Norway, Poland, Portugal and 4 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: